Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: Prescribing patterns, patient-level determinants of use, and patient-reported side effects

Arthritis Research and Therapy

Volumn 13, Issue 5, 2011, Pages

  Smith, Christopher J ^a   Sayles, Harlan ^a   Mikuls, Ted R ^a   Michaud, Kaleb ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; MINOCYCLINE; PREDNISONE; ANTIRHEUMATIC AGENT;

ABDOMINAL PAIN; ADULT; AGE; ARTICLE; CAUCASIAN; COMORBIDITY; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DIZZINESS; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEARTBURN; HUMAN; INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBSERVATIONAL STUDY; PATIENT-REPORTED OUTCOME; PHOTOSENSITIVITY; PRESCRIPTION; PRURITUS; PURPURA; RACE DIFFERENCE; RASH; RHEUMATOID ARTHRITIS; RHEUMATOLOGIST; SHORT FORM 36; SIDE EFFECT; SKIN DISEASE; TINNITUS; AGED; CLINICAL PRACTICE; COMMUNITY CARE; COMPARATIVE STUDY; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMMUNITY HEALTH SERVICES; DOXYCYCLINE; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MINOCYCLINE; PATIENT SATISFACTION; PHYSICIAN'S PRACTICE PATTERNS; TREATMENT OUTCOME;

EID: 80054114703     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3491     Document Type: Article

References (39)

1. Sapadin AN, Fleischmajer R: Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006, 54:258-265
2. Voils SA, Evans ME, Lane MT, Schosser RH, Rapp RP: Use of macrolides and tetracyclines for chronic inflammatory diseases. Ann Pharmacother 2005, 39:86-94
3. Webster G, Del Rosso JQ: Anti-inflammatory activity of tetracyclines. Dermatol Clin 2007, 25:133-135, v
4. Greenwald RA, Moak SA, Ramamurthy NS, Golub LM: Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. J Rheumatol 1992, 19:927-938
5. Greenwald RA: Tetracyclines may be therapeutically beneficial in rheumatoid arthritis. J Clin Rheumatol 1995, 1:185-189
6. Golub LM: Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dental Res 1998, 12:12-26
7. Langevitz P, Bank I, Zemer D, Book M, Pras M: Treatment of resistant rheumatoid arthritis with minocycline: an open study. J Rheumatol 1992, 19:1502-1504
8. Tilley BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, Clegg DO, Leisen JC, Buckley L, Cooper SM, Duncan H, Pillemer SR, Tuttleman M, Fowler SE: Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med 1995, 122:81-89
9. Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BA: Minocycline in active rheumatoid arthritis. A double-blind, placebocontrolled trial. Arthritis Rheum 1994, 37:629-636
10. O'Dell JR, Haire CE, Palmer W, Drymalski W, Wees S, Blakely K, Churchill M, Eckhoff PJ, Weaver A, Doud D, Erikson N, Dietz F, Olson R, Maloley P, Klassen LW, Moore GF: Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebocontrolled trial. Arthritis Rheum 1997, 40:842-848
11. O'Dell JR, Paulsen G, Haire CE, Blakely K, Palmer W, Wees S, Eckhoff PJ, Klassen LW, Churchill M, Doud D, Weaver A, Moore GF: Treatment of early seropositive rheumatoid arthritis with minocycline: four-year followup of a double-blind, placebo-controlled trial. Arthritis Rheum 1999, 42:1691-1695
12. O'Dell JR, Blakely KW, Mallek JA, Eckhoff PJ, Leff RD, Wees SJ, Sems KM, Fernandez AM, Palmer WR, Klassen LW, Paulsen GA, Haire CE, Moore GF: Treatment of early seropositive rheumatoid arthritis: a two-year, doubleblind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001, 44:2235-2241
13. Van der Laan W, Molenaar E, Ronday K, Verheijen J, Breedveld F, Greenwald R, Dijkmans B, TeKoppele J: Lack of effect of doxycycline on disease activity and joint damage in patients with rheumatoid arthritis. A double blind, placebo controlled trial. J Rheumatol 2001, 28:1967-1974
14. St. Clair EW, Wilkinson WE, Pisetsky DS, Sexton DJ, Drew R, Krause VB, Greenwald RA: The effects of intravenous doxycycline therapy for rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2001, 44:1043-1047
15. O'Dell JR, Elliott JR, Mallek JA, Mikuls TR, Weaver CA, Glickstein S, Blakely KM, Hausch R, Leff RD: Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. Arthritis Rheum 2006, 54:621-627
16. Stone M, Fortin PR, Pacheco-Tena C, Inman RD: Should tetracycline treatment be used more extensively for rheumatoid arthritis Metaanalysis demonstrates clinical benefit with reduction in disease activity. J Rheumatol 2003, 30:2112-2122
17. Wolfe F, Michaud K: Data collection, maintenance, and analysis for rheumatic disease research. Rheum Dis Clin North Am 2004, 30:753-768, vi
18. Wolfe F, Michaud K: A brief introduction to the National Data Bank for Rheumatic Diseases. Clin Exp Rheumatol 2005, 23:S168-S171
19. Wolfe F, Michaud K: The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. Rheumatology (Oxford) 2010, 50:16-24
20. Michaud K, Messer J, Choi HK, Wolfe F: Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 2003, 48:2750-2762
21. Michaud K, Wolfe F: Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007, 21:885-906
22. Ware JE, Gandek B: Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998, 51:903-912
23. Fries JF, Spitz P, Kraines RG, Holman HR: Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23:137-145
24. Wolfe F, Michaud K, Pincus T: A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol 2005, 32:2410-2415
25. Wolfe F, Rasker JJ, Boers M, Wells GA, Michaud K: Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum 2007, 57:935-942
26. Suresh E: Use of minocycline in rheumatoid arthritis: a district general hospital experience. Ann Rheum Dis 2004, 63:1354
27. Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P: Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000, 2:CD000959
28. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P: Sulfasalazine for rheumatoid arthritis. Cochrane Database Syst Rev 2000, 2:CD000958
29. Clark P, Tugwell P, Bennet K, Bombardier C, Shea B, Wells G, Suarez-Almazor ME: Injectable gold for rheumatoid arthritis. Cochrane Database Syst Rev 2000, 2:CD000520
30. Rosenstein ED: Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis. Inflammation 2004, 28:311-318
31. Lundberg K: Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 2008, 58:3009-3019
32. Wegner N: Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 2010, 233:34-54
33. Wegner N, Wait R, Sroka A, Eick S, Nguyen KA, Lundberg K, Kinloch A, Culshaw S, Potempa J, Venables PJ: Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 2010, 62:2662-2672
34. Hitchon CA: Antibodies to porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives. J Rheumatol 2010, 37:1105-1112
35. Felson DT, Anderson JJ, Meenan RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990, 33:1449-1461
36. Roberts G, Capell HA: The frequency and distribution of minocycline induced hyperpigmentation in a rheumatoid arthritis population. J Rheumatol 2006, 33:1254-1257
37. Fay BT, Whiddon AP, Puumala S, Black NA, O'Dell JR, Mikuls TR: Minocycline-induced hyperpigmentation in rheumatoid arthritis. J Clin Rheumatol 2008, 14:17-20
38. Smith K, Leyden JJ: Safety of doxycycline and minocycline: a systematic review. Clin Ther 2005, 27:1329-1342
39. Wolfe F, Hawley DJ, Cathey MA: Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990, 17:994-1002